Katya Sapunarova

Chief Assistant Professor
Department of Hematology, Medical University of Plodiv
Plodiv, Plovdiv, Bulgaria

Presentation(s):

• LB 01.1 - Safety, tolerability, and efficacy of mezagitamab (TAK-079) in chronic or persistent primary immune thrombocytopenia: Interim results from a phase 2, randomized, double-blind, placebo-controlled study

  Sunday, June 23, 2024
  09:30 – 09:45 ICT